Opinion|Videos|September 27, 2024
Implications of Combination Regimens for R/R MM
Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the potential role and implications of incorporating bispecifics into combination regimens for the treatment of R/R MM?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
5